StockStory Flags Amgen, BrightSpring as Buys Despite Wall Street Caution; Warns on Republic Bancorp

StockStory’s independent analysis identifies Amgen (NASDAQ:AMGN) and BrightSpring Health Services (NASDAQ:BTSG) as buying opportunities despite bearish Wall Street sentiment, while cautioning against Republic Bancorp (NASDAQ:RBCA.A), the research firm said June 1, 2026. Amgen shares traded at $336.71 on June 1, with a consensus price target of $352.23 implying a 4.6% return, supported by a forward price-to-sales ratio of 4.8 times. BrightSpring changed hands at $61.24, near its $61.40 target, with a forward price-to-earnings ratio of 34.5 times. Republic Bancorp stood at $80.94, a 1.3 times forward price-to-book valuation, versus a target of $80 suggesting a 1.2% decline. The firm noted that Wall Street analysts rarely issue negative ratings to protect other business lines, making the targets significant.